Regulation of the Innate and Adaptive Immune Responses by Stat-3 Signaling in Tumor Cells
Overview
Molecular Biology
Authors
Affiliations
Although tumor progression involves processes such as tissue invasion that can activate inflammatory responses, the immune system largely ignores or tolerates disseminated cancers. The mechanisms that block initiation of immune responses during cancer development are poorly understood. We report here that constitutive activation of Stat-3, a common oncogenic signaling pathway, suppresses tumor expression of proinflammatory mediators. Blocking Stat-3 in tumor cells increases expression of proinflammatory cytokines and chemokines that activate innate immunity and dendritic cells, leading to tumor-specific T-cell responses. In addition, constitutive Stat-3 activity induces production of pleiotropic factors that inhibit dendritic cell functional maturation. Tumor-derived factors inhibit dendritic cell maturation through Stat-3 activation in progenitor cells. Thus, inhibition of antitumor immunity involves a cascade of Stat-3 activation propagating from tumor to dendritic cells. We propose that tumor Stat-3 activity can mediate immune evasion by blocking both the production and sensing of inflammatory signals by multiple components of the immune system.
Jin Z, Zhou F, Wang Z, Li H Cancer Rep (Hoboken). 2025; 8(3):e70136.
PMID: 40035422 PMC: 11877328. DOI: 10.1002/cnr2.70136.
STAT signaling pathways in immune cells and their associated mechanisms in cancer pathogenesis.
Sohrabi S, Alipour S, Ghahramanipour Z, Masoumi J, Baradaran B Bioimpacts. 2025; 15:30030.
PMID: 39963570 PMC: 11830145. DOI: 10.34172/bi.30030.
Targeting intracellular proteins with cell type-specific functions for cancer immunotherapy.
Carelock M, Master R, Kim M, Jin Z, Wang L, Maharjan C Life Med. 2025; 2(3):lnad019.
PMID: 39872303 PMC: 11749652. DOI: 10.1093/lifemedi/lnad019.
Mutant p53-Mediated Tumor Secretome: Bridging Tumor Cells and Stromal Cells.
Qiu L, Ma Z, Wu X Genes (Basel). 2025; 15(12.
PMID: 39766882 PMC: 11675497. DOI: 10.3390/genes15121615.
Local CpG- siRNA treatment improves antitumor effects of immune checkpoint inhibitors.
Zhang C, Huang R, Ren L, Martincuks A, Song J, Kortylewski M Mol Ther Nucleic Acids. 2024; 35(4):102357.
PMID: 39618825 PMC: 11605413. DOI: 10.1016/j.omtn.2024.102357.